The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Referral and transplant-timing decisions in AML: advice for community physicians
Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, shares advice for community physicians on referral and transplant-timing decisions for patients with acute myeloid leukemia (AML). Dr Pusic emphasizes the importance of early referral and risk stratification in enabling timely molecular testing and informing treatment decisions. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think again that advice for community physicians is to refer early because sometimes it’s important to implement some of these treatments early on when we plan the regimen for people going forward and it’s also important to do appropriate testing early on so that we know what is the molecular profile of the disease and what are potential targeted therapies, what they could be, and to add them early on through induction regimens...
I think again that advice for community physicians is to refer early because sometimes it’s important to implement some of these treatments early on when we plan the regimen for people going forward and it’s also important to do appropriate testing early on so that we know what is the molecular profile of the disease and what are potential targeted therapies, what they could be, and to add them early on through induction regimens. So it’s important to re-stratify these patients to know kind of what is going to be the path forward. Is it somebody who is potentially curable just with chemotherapy and targeted therapy, or is it somebody who will need to go to transplant? Also, I think doing this approach where we kind of risk stratify these patients, we can know what therapies and we can also in a larger center enroll them possibly in clinical trials, testing some newer agents that might be very beneficial for them that might not be available in community practices. I think that’s probably the most important kind of a point to make here.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
